A review published in the journal Nutrients, led by researchers at the University of Rzeszow in Poland, looked at whether ergothioneine (ET), a thiol antioxidant found in mushrooms and some other foods, can protect the brain against neurodegeneration. The authors concluded that ET has shown neuroprotective effects in experimental models and deserves further study as a possible preventive or therapeutic agent. They were also clear that its clinical effectiveness in people has not been established.
Much of the interest comes from observational studies. Blood ET levels fell with age in one cohort of older adults, and people with mild cognitive impairment had significantly lower levels than healthy peers. Lower levels were also found in people with Parkinson's disease, and in one longitudinal study of 470 people without cognitive impairment at baseline, lower ET was linked to faster declines in several cognitive domains. The review is careful to point out that these links cannot show whether low ET contributes to disease or whether the body simply uses up more of the antioxidant when oxidative stress is high. The review also cites conflicting results, including one study that connected higher serum ET with increased Alzheimer's risk.
Laboratory and animal work is more encouraging. ET protected mouse hypothalamic neurons from death by suppressing excess reactive oxygen species, improved cell viability in human brain endothelial cells under oxidant stress, and reduced behavioral and cognitive deficits in mouse models of Alzheimer's and Parkinson's. Some cell experiments used concentrations higher than humans can reach, and many animal doses exceeded typical dietary intake. In humans, small trials have reported mixed results: a 16-week ET course improved subjective sleep quality in middle-aged adults with attention or memory complaints, and a 20 mg/day treatment for four weeks eased sleep difficulties in people with sleep complaints and anxiety. The review's authors suggest sleep changes might precede Parkinson's motor symptoms by years, so ET could conceivably affect disease onset, but they stress this is unproven.
For readers following the field, the significance lies mainly in the research direction. The mechanisms the authors describe, including antioxidant activity, activation of the Nrf2 antioxidant pathway, and reduced inflammatory signaling, give scientists specific hypotheses to test. The review itself states that the suggestion that ET supplementation or ET-rich diets could help prevent or delay neurodegeneration is not yet adequately supported by human studies. Larger, long-term randomized trials using purified ET would be needed before such claims could be evaluated.